Zealand Pharma Q3 2026 Operating Loss Narrows to DKK 54M from DKK 461M

Zealand Pharma reported a Q3 2026 operating loss of DKK 54 million, a sharp improvement from the DKK 461 million loss in Q3 2025. The narrowing loss suggests improved cost control or revenue growth, but the underlying drivers are not specified. This is a positive earnings development for the company, though not a macro-level market signal.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works